Where does UroGen Pharma Ltd. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), UroGen Pharma Ltd. ranks #21,979 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does UroGen Pharma Ltd. hold?

UroGen Pharma Ltd. holds 13 US utility patents granted between 2017 and 2025, spanning 11 technology areas.

What is UroGen Pharma Ltd.'s Innovation Score?

UroGen Pharma Ltd. has an Innovation Score of 34.2 out of 100 (47th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does UroGen Pharma Ltd. focus on?

UroGen Pharma Ltd.'s top technology area is A61K (Preparations FOR Medical, Dental OR Toiletry Purposes) with 12 patents, ranking #1,877 of 7,163 assignees active in that subclass. Grants appear in 11 CPC subclasses total.

Is UroGen Pharma Ltd.'s patent grant rate increasing or decreasing?

UroGen Pharma Ltd.'s recent grant velocity is -33% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for UroGen Pharma Ltd.'s patents?

UroGen Pharma Ltd.'s patents average 14.9 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the UroGen Pharma Ltd. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

UroGen Pharma Ltd.

USPTO PatentsView assignee record - 13 granted patents across 11 technology areas, recorded in grant years 2017–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61K (Preparations FOR Medical, Dental OR Toiletry Purposes).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Urogen ranks #21,979 of 49,997 tracked US assignees by granted-patent volume, with 13 patents across 11 technology areas.

#21,979
of 49,997 US assignees by volume: 47th percentile
by Innovation Score (34.2/100): 14.9
avg claims per patent: -33%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R21979 · Foreign Corporation #21,979 · 13 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-FOCUS · INNOV-THIN · CLAIMS-RICH · TYPE-FRNCORP · VEL-DOWN · BOOK-FULL

GRANTS-MICRO 13 grants
MID-PACK #21,979/49,997
PHOTO-FINISH Union Optech
CPC-FOCUS A61K · 11 areas
INNOV-THIN 34.2/100
CLAIMS-RICH 14.9 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-DOWN -33% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Union Optech Co., Ltd. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Urogen’s 34.2 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 9.1 pts (27%) Velocity 4.4 pts (13%) Breadth 11.7 pts (34%) Claim depth 9.0 pts (26%)

Qualcomm Incorporated · highest

85
UroGen Pharma · this assignee

34
3D Lighting… · lowest

7

What this shows Urogen's Innovation Score is 34.2/100 (47th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Urogen?

Each dot is one of Urogen’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Urogen’s own 14.9 claims/patent is at or below the 17.4 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Urogen vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Urogen's grants concentrate

UroGen Pharma Ltd. is a focused PatentsView assignee: 11 CPC subclasses with 92.3% of grants classified under A61K (Preparations FOR Medical, Dental OR Toiletry Purposes). Peak complete grant year is 2018 (3 grants) versus a trough of 1 in 2019. By volume, Urogen sits between UniZeo Co., Ltd. and Vanguard Seed, Inc..

Urogen's three-year grant acceleration

UroGen Pharma Ltd. shows 2 grants in 2022–2024 against only 3 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Unizeo

13
Union Optech

13
Universidade de S…

13
Universitaet der…

13
Urugus

13
Vadovations

13
Valor Fire Safety

13
Vanguard Seed

13
Urogen Pharma ◀

13

What this shows UroGen holds 13 patents at rank #21,979, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near UroGen

By rank, the assignees closest to #21,979 in granted patent volume.

Leaders in A61K (Preparations FOR Medical)

Other assignees with the most granted patents in UroGen's primary technology class.

Urogen's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

34 47th percentile higher than 47% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2017–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2017–2019 baseline. Full figures in the table below.

View data table

UroGen Pharma Ltd. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2017	2	15.4%
2018	3	23.1%
2019	1	7.7%
2020	1	7.7%
2021	1	7.7%
2023	1	7.7%
2024	1	7.7%
2025partial year	3	23.1%

Which technologies does UroGen Pharma Ltd. patent most?

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 12

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 7

C12Y - Enzymes 2

A61B - DIAGNOSIS; SURGERY; Identification 2

A61L - Methods OR Apparatus FOR Sterilising Materials OR Objects IN GENERAL; Disinfection, Sterilisation OR Deodorisation OF AIR; Chemical Aspects OF Bandages, Dressings, Absorbent Pads OR Surgical ARTICLES; Materials FOR Bandages, Dressings, Absorbent Pads OR Surgical Articles 2

A61M - Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor 2

C07K - Peptides 2

Y02A - Technologies FOR Adaptation TO Climate Change 1

C07F - Acyclic, Carbocyclic OR Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium OR Tellurium 1

A61N - ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy 1

A61F - Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive DEVICES; FOMENTATION; Treatment OR Protection OF Eyes OR EARS; Bandages, Dressings OR Absorbent PADS; Firs 1

Top 11 of 11 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

UroGen Pharma Ltd.'s patent record in context - here's where to go next.

UroGen Pharma Ltd.'s lead technology class is A61K (Preparations FOR Medical, Dental OR Toiletry Purposes), 92.3% of its portfolio - see every assignee active in that class. Explore A61K
Ranked #21,979 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare UroGen Pharma Ltd. against UniZeo Co., Ltd., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 34.2/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.